WO2018015595A3 - Compuestos para el tratamiento de las enfermedades causadas por parásitos del género leishmania - Google Patents

Compuestos para el tratamiento de las enfermedades causadas por parásitos del género leishmania Download PDF

Info

Publication number
WO2018015595A3
WO2018015595A3 PCT/ES2017/070502 ES2017070502W WO2018015595A3 WO 2018015595 A3 WO2018015595 A3 WO 2018015595A3 ES 2017070502 W ES2017070502 W ES 2017070502W WO 2018015595 A3 WO2018015595 A3 WO 2018015595A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
treatment
diseases caused
leishmania genus
parasites
Prior art date
Application number
PCT/ES2017/070502
Other languages
English (en)
French (fr)
Other versions
WO2018015595A2 (es
Inventor
José Antonio GÓMEZ VIDAL
Mónica Díaz Gavilán
Francisco Franco Montalbán
Francisco MORILLAS MÁRQUEZ
Victoriano CORPAS LÓPEZ
Joaquina MARTÍN SÁNCHEZ
Margarita LÓPEZ-VIOTA GALLARDO
Julián López-Viota Gallardo
Original Assignee
Universidad De Granada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES201630944A external-priority patent/ES2607628B1/es
Priority claimed from ES201730208A external-priority patent/ES2608476B1/es
Application filed by Universidad De Granada filed Critical Universidad De Granada
Publication of WO2018015595A2 publication Critical patent/WO2018015595A2/es
Publication of WO2018015595A3 publication Critical patent/WO2018015595A3/es

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere auna familia de compuestos que resultan efectivos frente a parásitos del género Leishmania, preferentemente causadas por L. infantum, L. major o L. tropica, y que presentan una baja toxicidad incluso a dosis altas del compuesto. La invención también se refiere a composiciones farmacéuticas, preferentemente aptas para administración oral o tópica,que comprenden esos compuestos y a su uso como medicamento para el tratamiento de leishmaniosis visceral, canina o cutánea.
PCT/ES2017/070502 2016-07-11 2017-07-11 Compuestos para el tratamiento de las enfermedades causadas por parásitos del género leishmania WO2018015595A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES201630944A ES2607628B1 (es) 2016-07-11 2016-07-11 Compuestos para el tratamiento de la leishmaniosis
ESP201630944 2016-07-11
ES201730208A ES2608476B1 (es) 2017-02-20 2017-02-20 Compuestos para el tratamiento de las enfermedades causadas por parásitos del género leishmania
ESP201730208 2017-02-20

Publications (2)

Publication Number Publication Date
WO2018015595A2 WO2018015595A2 (es) 2018-01-25
WO2018015595A3 true WO2018015595A3 (es) 2018-03-22

Family

ID=60993303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2017/070502 WO2018015595A2 (es) 2016-07-11 2017-07-11 Compuestos para el tratamiento de las enfermedades causadas por parásitos del género leishmania

Country Status (1)

Country Link
WO (1) WO2018015595A2 (es)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013045734A1 (es) * 2011-09-26 2013-04-04 Universidad De Granada Compuestos con actividad antileishmania
WO2017199028A1 (en) * 2016-05-18 2017-11-23 The University Court Of The University Of Edinburgh Bioorthogonal compounds comprising a propargyl group for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013045734A1 (es) * 2011-09-26 2013-04-04 Universidad De Granada Compuestos con actividad antileishmania
WO2017199028A1 (en) * 2016-05-18 2017-11-23 The University Court Of The University Of Edinburgh Bioorthogonal compounds comprising a propargyl group for treating cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIELIAUSKAS, A.V. ET AL.: "Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 17, 8 February 2007 (2007-02-08), pages 2216 - 2219, XP022009235, ISSN: 0960-894X *
DANIEL, K.B. ET AL.: "Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, 2015, pages 4812 - 4821, XP055497879, ISSN: 0022-2623, [retrieved on 20150514] *
GIANNINI, G. ET AL.: "Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 25, 19 December 2014 (2014-12-19), pages 459 - 461, XP029131262, ISSN: 0960-894X, Retrieved from the Internet <URL:http://dx.doi.org/10.1016/jbcl.2014.12.051> *
LEONIDOVA, A. ET AL.: "Selective Photorelease of an Organometallic- Containing Enzyme Inhibitor", ORGANOMETALLICS, vol. 35, 7 March 2016 (2016-03-07), pages 851 - 854, XP055497894, ISSN: 0276-7333 *
RUBIO-RUIZ, B. ET AL.: "Efficient Palladium-Triggered Release of Vorinostat from a Bioorthogonal Precursor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, 27 October 2016 (2016-10-27), pages 9974 - 9980, XP055395430, ISSN: 0022-2623 *
STEC, J. ET AL.: "Synthesis, Biological Evaluation, and Structure-Activity Relationships of N-Benzoyl-2-hydroxybenzamides as Agents Active against P. falciparum (K1 strain), Trypanosomes, and Leishmania", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, 21 February 2012 (2012-02-21), pages 3088 - 3100, XP055107839, ISSN: 0022-2623, Retrieved from the Internet <URL:http://dx.doi.org/10.1021/jm2015183.> *

Also Published As

Publication number Publication date
WO2018015595A2 (es) 2018-01-25

Similar Documents

Publication Publication Date Title
EP4252848A3 (en) Oxysterols and methods of use thereof
UY33479A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento
WO2011106729A3 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
WO2015120110A3 (en) Novel pharmaceutical formulations
EP4227304A3 (en) Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA202090573A1 (ru) Составы нирапариба
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
WO2007009723A3 (en) Azepane- or azocane-substituted pyrazoline derivatives, their preparation and use as medicaments
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MX2019012522A (es) Compuestos y metodos terapeuticos.
EA033083B1 (ru) Циклические соединения
WO2017034242A3 (ko) 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
BR112022009533A2 (pt) Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica
EA201070898A1 (ru) Новое производное хиназолин-2,4-диона и лекарственные композиции на его основе для профилактики и лечения заболевания, обусловленного поражением черепно-мозгового нерва
WO2018015595A3 (es) Compuestos para el tratamiento de las enfermedades causadas por parásitos del género leishmania
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser
ECSP20003493A (es) Composiciones farmacéuticas
WO2013151597A3 (en) (1,2,3-triazolyl) sulfonyl derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17830535

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17830535

Country of ref document: EP

Kind code of ref document: A2